Date | Price Target | Rating | Analyst |
---|---|---|---|
7/24/2024 | $75.00 → $90.00 | Equal Weight → Underweight | Barclays |
6/27/2024 | $113.00 | Buy | Janney |
6/26/2024 | $110.00 | Buy | BTIG Research |
6/3/2024 | Buy | CLSA | |
3/25/2024 | $110.00 → $95.00 | Buy → Hold | Truist |
11/3/2023 | $79.00 → $82.00 | Overweight → Neutral | Alembic Global Advisors |
9/28/2023 | $86.00 | Buy | Deutsche Bank |
8/4/2023 | $61.00 → $85.00 | Neutral → Outperform | Robert W. Baird |
Barclays downgraded BWX Technologies from Equal Weight to Underweight and set a new price target of $90.00 from $75.00 previously
Janney initiated coverage of BWX Technologies with a rating of Buy and set a new price target of $113.00
BTIG Research initiated coverage of BWX Technologies with a rating of Buy and set a new price target of $110.00
2Q24 revenues of $681.5 million 2Q24 net income of $73.0 million, adjusted EBITDA(1) of $126.2 million 2Q24 diluted GAAP EPS of $0.79, non-GAAP(1) EPS of $0.82 BWXT-led JV awarded management and operations contract for the NNSA's Pantex Plant 2024 non-GAAP EPS(1) guidance revised to $3.10-$3.20 BWX Technologies, Inc. (NYSE:BWXT) ("BWXT", "we", "us" or the "Company") reported second quarter 2024 results. A reconciliation of non-GAAP results are detailed in Exhibit 1. "Second quarter results were ahead of our expectations driven by strong organic growth and crisp execution across our business lines," said Rex. D Geveden. "Our solid year-to-date performance provides us th
BWX Technologies, Inc. (NYSE:BWXT) will issue a press release detailing second quarter 2024 results on Monday, August 5, 2024, after market close and will host a conference call at 5:00 p.m. EDT. Listen-only participants are encouraged to participate and view the supporting presentation via the Internet at www.bwxt.com/investors. The dial-in numbers for participants are (U.S.) 1-888-596-4144 and (International) 1-646-968-2525; conference ID: 7880317. A replay of the call will remain available on the BWXT website for a limited time. About BWXT At BWX Technologies, Inc. (NYSE:BWXT), we are People Strong, Innovation Driven. A U.S.-based company, BWXT is a Fortune 1000 and Defense News To
1Q24 revenues of $604.0 million 1Q24 net income of $68.5 million, adjusted EBITDA(1) of $115.2 million 1Q24 diluted GAAP EPS of $0.75, non-GAAP(1) EPS of $0.76 Announced expansion of Cambridge manufacturing plant; enhancing capabilities to serve the global CANDU and Small Modular Reactor markets Reaffirms 2024 non-GAAP EPS(1) guidance of $3.05-$3.20 BWX Technologies, Inc. (NYSE:BWXT) ("BWXT", "we", "us" or the "Company") reported first quarter 2024 results. A reconciliation of non-GAAP results are detailed in Exhibit 1. "We started 2024 with solid operating results in each of our business segments, both financially and strategically," said Rex. D. Geveden, president and ch
4 - BWX Technologies, Inc. (0001486957) (Issuer)
4 - BWX Technologies, Inc. (0001486957) (Issuer)
4 - BWX Technologies, Inc. (0001486957) (Issuer)
Barclays analyst David Strauss downgrades BWX Technologies (NYSE:BWXT) from Equal-Weight to Underweight and raises the price target from $75 to $90.
Actinium-225 (Ac-225) is a critical medical isotope used to kill cancer cells while minimizing the impact to healthy tissues.
BWXT Medical Ltd., a subsidiary of BWX Technologies, Inc. (NYSE:BWXT) and NorthStar Medical Radioisotopes, LLC (NorthStar) today announced that they have signed a Master Services Agreement (MSA), which will facilitate the production of actinium-225 (Ac-225), a critical medical isotope used to kill cancer cells while minimizing the impact to healthy tissues. Medical isotopes are essential for a wide range of diagnostic and therapeutic procedures, including cancer treatments and advanced imaging techniques. Pursuant to the multi-year MSA, the companies will work together to process and purify radium-226. The scope of the agreement also includes potential target design projects and exploration
BWX Technologies, Inc. (NYSE:BWXT) today announced a contract from the National Nuclear Security Administration (NNSA) to complete a yearlong engineering study to evaluate options for the deployment of a centrifuge pilot plant that would establish a domestic uranium enrichment capability for national security purposes. Awarded to BWXT subsidiary Nuclear Fuel Services, Inc., this contract represents the next phase of the NNSA's Domestic Uranium Enrichment Centrifuge Experiment (DUECE). The NNSA's DUECE program, developed and managed by Oak Ridge National Laboratory (ORNL), is intended to preserve and advance uranium enrichment expertise and technology for current and future U.S. national s
BWX Technologies, Inc. (NYSE:BWXT) has appointed Vittorio Puppo as president of BWXT Medical Ltd., effective August 12, 2024. In his new role, Puppo will focus on advancing the business' mission to deliver high-quality nuclear medical products and solutions that improve patient outcomes worldwide. Puppo brings a wealth of experience to BWXT Medical, with over 30 years of experience in the areas of imaging, nuclear medicine, radiation therapy and biotech, in both Europe and North America. In his most recent roles, he served as chief operating officer of Radiopharm Theranostics and held various positions with Bracco. These include chief marketing and strategy officer of Bracco Imaging, pres
2Q24 revenues of $681.5 million 2Q24 net income of $73.0 million, adjusted EBITDA(1) of $126.2 million 2Q24 diluted GAAP EPS of $0.79, non-GAAP(1) EPS of $0.82 BWXT-led JV awarded management and operations contract for the NNSA's Pantex Plant 2024 non-GAAP EPS(1) guidance revised to $3.10-$3.20 BWX Technologies, Inc. (NYSE:BWXT) ("BWXT", "we", "us" or the "Company") reported second quarter 2024 results. A reconciliation of non-GAAP results are detailed in Exhibit 1. "Second quarter results were ahead of our expectations driven by strong organic growth and crisp execution across our business lines," said Rex. D Geveden. "Our solid year-to-date performance provides us th
10-Q - BWX Technologies, Inc. (0001486957) (Filer)
8-K - BWX Technologies, Inc. (0001486957) (Filer)
SD - BWX Technologies, Inc. (0001486957) (Filer)
SC 13G/A - BWX Technologies, Inc. (0001486957) (Subject)
SC 13G/A - BWX Technologies, Inc. (0001486957) (Subject)
SC 13G/A - BWX Technologies, Inc. (0001486957) (Subject)
BWX Technologies, Inc. (NYSE:BWXT) has appointed Vittorio Puppo as president of BWXT Medical Ltd., effective August 12, 2024. In his new role, Puppo will focus on advancing the business' mission to deliver high-quality nuclear medical products and solutions that improve patient outcomes worldwide. Puppo brings a wealth of experience to BWXT Medical, with over 30 years of experience in the areas of imaging, nuclear medicine, radiation therapy and biotech, in both Europe and North America. In his most recent roles, he served as chief operating officer of Radiopharm Theranostics and held various positions with Bracco. These include chief marketing and strategy officer of Bracco Imaging, pres
SMR Supplier Group Will Support Global Deployment of BWRX-300 Design BWXT Canada Ltd., a subsidiary of BWX Technologies, Inc. (NYSE:BWXT), has been selected as the first qualified supply chain company to join the GE Vernova nuclear business' supplier group that will advance the global deployment of the BWRX-300 small modular reactor (SMR). The purpose of the supplier group is to ensure a reliable, cost effective and innovative process for the manufacture and commercialization of the BWRX-300 currently under design by GE Vernova's nuclear business, GE Hitachi Nuclear Energy (GEH). Suppliers who meet pre-defined criteria, customer requirements and demonstrate a willingness to internally i
MONTREAL, April 11, 2024 /CNW/ - AtkinsRéalis, a fully integrated professional services and project management company with offices around the world, welcomes BWXT Canada Ltd., a company with over 60 years of expertise and experience in the designing, manufacturing, commissioning, and servicing of nuclear power generation equipment, as a new ambassador in support of the Canadians for CANDU campaign. The Canadians for CANDU campaign was launched on February 28, 2024. Spearheaded by Co-Chairs the Right Honourable Jean Chretien and former Ontario Premier Mike Harris, the campaign